These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 2515724)

  • 1. Selegiline as primary treatment in early phase Parkinson's disease--an interim report.
    Myllylä VV; Sotaniemi KA; Tuominen J; Heinonen EH
    Acta Neurol Scand Suppl; 1989; 126():177-82. PubMed ID: 2515724
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selegiline as initial treatment in de novo parkinsonian patients.
    Myllylä VV; Sotaniemi KA; Vuorinen JA; Heinonen EH
    Neurology; 1992 Feb; 42(2):339-43. PubMed ID: 1736162
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selegiline (1-deprenyl) and low-dose levodopa treatment of Parkinson's disease. A double-blind crossover trial.
    Presthus J; Berstad J; Lien K
    Acta Neurol Scand; 1987 Sep; 76(3):200-3. PubMed ID: 3120487
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Double-blind, crossover placebo controlled trial of selegiline in Parkinson's disease--an interim analysis.
    Teychenne PF; Parker S
    Acta Neurol Scand Suppl; 1989; 126():119-25. PubMed ID: 2515717
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selegiline in the treatment of daily fluctuations in disability of parkinsonian patients with long-term levodopa treatment.
    Heinonen EH; Rinne UK; Tuominen J
    Acta Neurol Scand Suppl; 1989; 126():113-8. PubMed ID: 2515716
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selegiline and levodopa in early or moderately advanced Parkinson's disease: a double-blind controlled short- and long-term study.
    Sivertsen B; Dupont E; Mikkelsen B; Mogensen P; Rasmussen C; Boesen F; Heinonen E
    Acta Neurol Scand Suppl; 1989; 126():147-52. PubMed ID: 2515720
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selegiline as a primary treatment of Parkinson's disease.
    Myllylä VV; Sotaniemi KA; Vuorinen JA; Heinonen EH
    Acta Neurol Scand Suppl; 1991; 136():70-2. PubMed ID: 1801540
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selegiline delays the onset of disability in de novo parkinsonian patients. Swedish Parkinson Study Group.
    Pålhagen S; Heinonen EH; Hägglund J; Kaugesaar T; Kontants H; Mäki-Ikola O; Palm R; Turunen J
    Neurology; 1998 Aug; 51(2):520-5. PubMed ID: 9710028
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selegiline in de novo parkinsonian patients: the French selegiline multicenter trial (FSMT).
    Allain H; Cougnard J; Neukirch HC
    Acta Neurol Scand Suppl; 1991; 136():73-8. PubMed ID: 1801541
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Symptomatic effect of selegiline in de novo Parkinsonian patients. The French Selegiline Multicenter Trial.
    Allain H; Pollak P; Neukirch HC
    Mov Disord; 1993; 8 Suppl 1():S36-40. PubMed ID: 8302306
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selegiline in the treatment of Parkinson's disease.
    Heinonen EH; Rinne UK
    Acta Neurol Scand Suppl; 1989; 126():103-11. PubMed ID: 2515715
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early selegiline therapy reduces levodopa dose requirement in Parkinson's disease.
    Myllylä VV; Heinonen EH; Vuorinen JA; Kilkku OI; Sotaniemi KA
    Acta Neurol Scand; 1995 Mar; 91(3):177-82. PubMed ID: 7793231
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effects of early selegiline therapy on long-term levodopa treatment and parkinsonian disability: an interim analysis of a Norwegian--Danish 5-year study. Norwegian-Danish Study Group.
    Larsen JP; Boas J
    Mov Disord; 1997 Mar; 12(2):175-82. PubMed ID: 9087975
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selegiline in the early and late phases of Parkinson's disease.
    Csanda E; Tárczy M
    J Neural Transm Suppl; 1987; 25():105-13. PubMed ID: 3123597
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Deprenyl (selegiline) combined with levodopa and a decarboxylase inhibitor in the treatment of Parkinson's disease.
    Presthus J; Hajba A
    Acta Neurol Scand Suppl; 1983; 95():127-33. PubMed ID: 6428145
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selegiline in de novo parkinsonian patients: the Finnish study.
    Myllylä VV; Sotaniemi KA; Vuorinen JA; Heinonen EH
    Mov Disord; 1993; 8 Suppl 1():S41-4. PubMed ID: 8302307
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparisons of therapeutic effects of levodopa, levodopa and selegiline, and bromocriptine in patients with early, mild Parkinson's disease: three year interim report. Parkinson's Disease Research Group in the United Kingdom.
    BMJ; 1993 Aug; 307(6902):469-72. PubMed ID: 8400928
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination of a dopamine agonist, MAO-B inhibitor and levodopa--a new strategy in the treatment of early Parkinson's disease.
    Rinne UK
    Acta Neurol Scand Suppl; 1989; 126():165-9. PubMed ID: 2515722
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selegiline as an adjunct to conventional levodopa therapy in Parkinson's disease. Experience with this type B monoamine oxidase inhibitor in 200 patients.
    Elizan TS; Yahr MD; Moros DA; Mendoza MR; Pang S; Bodian CA
    Arch Neurol; 1989 Dec; 46(12):1280-3. PubMed ID: 2511825
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selegiline as the primary treatment of Parkinson's disease--a long-term double-blind study.
    Myllylä VV; Sotaniemi KA; Hakulinen P; Mäki-Ikola O; Heinonen EH
    Acta Neurol Scand; 1997 Apr; 95(4):211-8. PubMed ID: 9150811
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.